SummitTX Capital’s Genmab GMAB Stock Holding History

SummitTX Capital’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$8.75M	Buy	318,408 +234,054	+277%	+$6.22M	0.23%	109
2026 Q1	$2.26M	Buy	+84,354	New	+$2.53M	0.07%	288

Other funds holding GMAB

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

SummitTX Capital's GMAB Position: Q2 2026 in Review

SummitTX Capital increased its Genmab (GMAB) stake by 277% in Q2 2026, buying an estimated $6.22M and bringing the position to 318,408 shares worth $8.75M. The position accounts for 0.23% of the portfolio, ranked #109.

SummitTX Capital first reported a position in GMAB in Q1 2026 and has held it in 2 quarters since. 289 funds tracked by Wall St. Rank hold GMAB as of Q2 2026.

SummitTX Capital held 318,408 shares of Genmab worth $8.75M as of Q2 2026.
SummitTX Capital bought 234,054 Genmab shares in Q2 2026, an estimated $6.22M.
Genmab made up 0.23% of SummitTX Capital's portfolio in Q2 2026, its #109 holding.
SummitTX Capital first reported a position in Genmab in Q1 2026 and has held it in 2 quarters since.
289 funds tracked by Wall St. Rank held Genmab as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.